Outsourcing Facilities — Registration and cGMP
Creates the outsourcing-facility category: a compounder that registers with FDA, complies with cGMP, reports adverse events, and is inspected on a risk-based schedule, in exchange for being able to compound without patient-specific prescriptions. Added by the Drug Quality and Security Act of 2013 following the 2012 fungal-meningitis outbreak.
What this does not cover
stated in the document's own scope- Covers registered outsourcing facilities compounding under cGMP, including without patient-specific prescriptions; traditional patient-specific compounding is the §503A route.
- Grants exemption from new-drug approval and adequate-directions-for-use labeling, but not from cGMP, which outsourcing facilities must follow.
- Defines the outsourcing-facility category and its federal oversight, not the full new-drug manufacturing and approval framework that branded and generic manufacturers follow.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
Section 503B of the Federal Food, Drug, and Cosmetic Act created the outsourcing-facility category for drug compounding. A compounder that elects to register with FDA as an outsourcing facility, complies with cGMP, reports adverse events, submits product-reporting information, and pays applicable fees may in return compound drugs — including for office stock — without a patient-specific prescription, subject to a risk-based inspection schedule. The category was designed for larger-volume compounding, offering a federal, cGMP-based route that sits between traditional patient-specific compounding and full drug manufacturing.
Scope & applicability
Facilities compounding sterile preparations for distribution to healthcare providers without individual prescriptions. Registration is voluntary in form but effectively mandatory for that business model.
Legal basis & how it acquires force
Section 503B was added to the Federal Food, Drug, and Cosmetic Act by the Drug Quality and Security Act of 2013, enacted in the wake of the 2012 fungal-meningitis outbreak traced to contaminated compounded products. Registration as an outsourcing facility is voluntary, but once elected it brings the facility under FDA cGMP, adverse-event reporting, and a risk-based FDA inspection schedule. Drugs compounded by a registered outsourcing facility that meets §503B’s conditions are exempt from new-drug approval and from the adequate-directions-for-use labeling requirement, but not from cGMP.
Document structure
| Part | Covers |
|---|---|
| Election and registration | Voluntary registration with FDA as an outsourcing facility |
| cGMP compliance | Compounding in compliance with current good manufacturing practice |
| Bulk drug substances | Use of bulk substances meeting specified conditions, including clinical-need criteria |
| Adverse event and product reporting | Reporting adverse events and submitting product and facility reports to FDA |
| Inspection and fees | Risk-based FDA inspection schedule and applicable establishment fees |
| Exemptions granted | Exemption from new-drug approval and adequate-directions-for-use labeling, but not cGMP |
Key requirements
- Registration with FDA as an outsourcing facility, with product reporting
- Compliance with cGMP for the preparations made
- Direct supervision by a licensed pharmacist
- Adverse-event reporting to FDA
- Bulk substances limited to the 503B list or drugs on the shortage list
- Labelling as required for compounded preparations
Implementation tips
- Build the quality system to sterile-manufacturing expectations from the start — media fills, EM with alert/action levels, validated processes and a real CAPA system
- Read the FDA 483s and warning letters issued to other outsourcing facilities by theme; the enforcement pattern in this sector is unusually consistent
- Do not rely on pharmacy-compounding precedent for validation scope; the applicable benchmark is Annex 1 and 21 CFR 211
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
Section 503B is the companion to §503A: where §503A defines traditional patient-specific compounding overseen substantially by state boards, §503B defines a federally registered, cGMP-based outsourcing route regulated directly by FDA. The cGMP that outsourcing facilities follow draws on the drug cGMP framework in 21 CFR Parts 210 and 211, with FDA guidance tailoring expectations to the sector. Both sections were enacted together in the Drug Quality and Security Act of 2013.
FD&C Act §503B: frequently asked questions
Quick answers to common questions about FD&C Act §503B.
What is an outsourcing facility under §503B?
A compounder that voluntarily registers with FDA, complies with cGMP, reports adverse events and product information, and is subject to a risk-based FDA inspection schedule — and may in return compound drugs, including office stock, without patient-specific prescriptions.
Why was §503B created?
It was added by the Drug Quality and Security Act of 2013 following the 2012 fungal-meningitis outbreak linked to contaminated compounded products, to provide a federal, cGMP-based route for larger-volume compounding.
Does a §503B facility have to follow cGMP?
Yes. Unlike §503A, the §503B exemptions cover new-drug approval and adequate-directions-for-use labeling but not cGMP — outsourcing facilities must compound in compliance with current good manufacturing practice.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.